High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development


1Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; 2Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada; 3Department of Medicine, Weill Cornell Cancer Center, Weill Cornell Medical College, New York, NY, USA; 4Department of Pathology and Laboratory Medicine, Weill Cornell Cancer Center, Weill Cornell Medical College, New York, NY, USA; 5Department of Urologic Sciences, Faculty of Medicine, University of British Columbia; 6Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada; *These authors contributed equally to this work.

Correspondence should be addressed to Yuzhuo Wang, PhD, or Colin Collins, PhD. Department of Urologic Sciences/Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z6. Email: ywang@bccrc.ca or ccollins@prostatecentre.com; Phone: 604-675-8013; FAX: 604-675-8019.
Running title: Next-generation models of prostate cancer

Keywords: prostate cancer models; cancer tissue xenografts; subrenal capsule; heterogeneity; neuroendocrine prostate cancer.

Financial support: Canadian Institutes of Health Research (YW), CECR (MG), Prostate Cancer Canada (CC, YW), Prostate Cancer Foundation (CC, YW), BC Cancer Foundation (YW), The Canadian Prostate Cancer Genome Network (CC), Coalition to Cure Prostate Cancer Young Investigator Award (AW), Prostate Cancer Foundation BC (AW).

Competing Interests: The authors declare that they have no competing interests.

Word Count (excluding references): 4986

Total number of figures and tables: 6

GEO accession number for microarray data: GSE41193
ABSTRACT

Standardized and reproducible pre-clinical models that recapitulate the dynamics of prostate cancer (PCa) are urgently needed. We established a bank of transplantable patient-derived PCa xenografts that capture the biological and molecular heterogeneity currently confounding prognostication and therapy development. Xenografts preserved the histopathology, genome architecture, and global gene expression of donor tumours. Moreover, their aggressiveness matched patient observations, and their response to androgen withdrawal correlated with tumor subtype. The panel includes the first xenografts generated from needle biopsy tissue obtained at diagnosis. This advance was exploited to generate independent xenografts from different sites of a primary site: enabling functional dissection of tumor heterogeneity. Prolonged exposure of adenocarcinoma xenografts to androgen withdrawal led to castration-resistant PCa, including the first-in-field model of complete transdifferentiation into lethal neuroendocrine PCa. Further analysis of this model supports the hypothesis that neuroendocrine PCa can evolve directly from adenocarcinoma via an adaptive response, and yielded a set of genes potentially involved in neuroendocrine transdifferentiation. We predict that these next-generation models will be transformative for advancing mechanistic understanding of disease progression, response to therapy and personalized oncology.
INTRODUCTION

Globally, prostate cancer is the second most commonly diagnosed cancer in men and accounts for 250,000 deaths annually (1). Although androgen deprivation therapy elicits rapid remission, tumors inevitably return as castrate-resistant prostate cancer (CRPC), which often remains androgen-dependent and is essentially untreatable (2). The development of novel therapeutics has been hampered in part through high clinical and biological heterogeneity and the lack of distinguishable histological subtypes. However, the age of next-generation sequencing and integrated genomics is providing increasing evidence for molecularly-defined subtypes. Although strict correlation with clinical outcome remains elusive, tumors can now be classified by their genome copy number, fusion gene profiles, mutational landscapes and even mRNA splicing patterns (3-7). To exploit emergent discoveries for mechanistic understanding and therapeutic advances, focus must now turn to the development of a new generation of preclinical models that capture the ‘omic’ diversity of prostate cancer.

Preclinical cancer models for in vivo drug tests are commonly based on immune-deficient mice carrying subcutaneous prostate cancer cell line xenografts. Unfortunately, these models fail to reproduce the diverse heterogeneity observed in the clinic, partly due to the increased homogeneity of established cell lines after long-term in vitro culturing. Furthermore, cell line xenografts rarely possess the tissue architecture of the original cancer specimens from which the cell lines were derived and, consequently, do not accurately represent the complex biochemical and physical interactions between the cancer cells and various components of their microenvironment as found in the original malignancies. Unsurprisingly therefore, cell line xenografts frequently fail to adequately predict the efficacy of anticancer agents in the clinic (8). Thus, only
~5% of potential new anti-cancer drugs, that have successfully passed in vivo tests, have significant efficacy in clinical trials and are approved for clinical usage by the U.S. Food & Drug Administration (9). The cost of these failures is estimated in the range of hundreds millions of dollars per drug (10).

In theory, patient-derived cancer tissue xenograft models, based on direct implantation of fresh cancer tissue specimens into immuno-deficient mice, (e.g., Nude, SCID mice) provide the needed clinical relevance. In other cancers, these xenografts retain the cellular heterogeneity, architectural and molecular characteristics of the original cancer and its microenvironment (11). However, development of prostate cancer tissue xenograft models has been hampered by low success rates, partly due to poor vascularization of the graft site, with engraftment only successful when applied to advanced cancers with high growth rates (e.g., metastatic tumors) (12-14). As such, existing models represent only a small proportion of cancer phenotypes and do not recapitulate disease heterogeneity (15, 16).

In contrast to the subcutaneous graft site, the subrenal capsule site is highly vascularized and associated with a very high take rate for most intact grafted tissues including benign human prostate tissue (17, 18). Recently, Risbridger and colleagues have also standardized a protocol for subrenal grafting of recombined localized human prostate epithelial tissue with mouse mesenchyme (19). They demonstrate the remarkable effectiveness of the subrenal site for modelling localized prostate tumours (20). Over the past few years, we have established a novel panel of transplantable patient-derived prostate tumor xenograft models, the LTL (Living Tumor Laboratory) series, from intact primary and metastatic clinical specimens via subrenal capsule grafting. Our xenografts retain the histopathological and molecular characteristics of their original parent tumors and represent several recently emerging molecular subtypes of prostate
cancer. Therefore, we present a panel of high-fidelity primary and metastatic prostate cancer models which accurately recapitulate biological and molecular heterogeneity. This publicly-available resource provides the urgently needed tools to advance mechanistic understanding of disease progression and response to therapy, and delivers clinically-relevant model systems for evaluation of preclinical drug efficacy and beyond.

METHODS

Materials and animals

Chemicals, stains, solvents and solutions were obtained from Sigma-Aldrich Canada Ltd, Oakville, ON, Canada, unless otherwise indicated. NOD SCID mice (NOD.CB17-Prkdcscid/J) were originally purchased from JAX lab and were bred in the breeding area of SPF level facility in Animal Resource Center (ARC), BC Cancer Research Centre. The breeding colonies were managed by ARC staff and delivered to experimental housing room after being weaned. The mice used for xenografts were 6-8 weeks old. All food, water and litter were sterilized prior to use. Temperature (20-21°C) and humidity (50-60%) were controlled. Daily light cycles were 12 h light and 12 h dark. Cages were changed fully once or twice a week.

Prostate cancer tissue acquisition

Specimens were obtained from patients following a protocol approved by the Clinical Research Ethics Board of the University of British Columbia (UBC) and the BC Cancer Agency. The specimens were examined, sectioned and selected by pathologists for histological analysis and xenografting. All patients signed a consent form approved by the Ethics Board (UBC Ethics board #: H09-01628 and H04-60131; VCHRI #: V09-0320 and V07-0058).
Subrenal capsule grafting and development of transplantable tumor lines

Within 24 hours of sample arrival, a minor portion of the tumor was fixed for histological analysis. The remainder of the tumors were cut into small pieces (1×3×3 mm³ in size) and grafted into subrenal capsule of male NOD-SCID mice supplemented with testosterone as previously described (18). After 3-6 months of growth (or earlier if required by the health status of the hosts), the animals were sacrificed in a CO₂ chamber for necropsy. Tumors were harvested and regrafted into NOD-SCID mice under the kidney capsules. The rapidly growing tumors (transplantable tumor lines) were consistently maintained by serial subrenal capsule transplantation. Static xenograft pieces were maintained by serial transplantation for up to three years. At each passage of rapidly growing tumors and at the last passage of static tumors, xenografts were harvested, measured and fixed for histopathological analysis. The hosts were sacrificed and examined for metastases of human origin in lymph nodes, lungs, livers, kidneys, spleens and bones (femur). Animal care and experiments were carried out in accordance with the guidelines of the Canadian Council on Animal Care.

Histopathology and immunohistochemistry

Preparation of paraffin-embedded tissue sections and immunohistochemical analyses were carried out as previously described (21). For histopathology, routine H&E staining was carried out. A rabbit polyclonal anti-AR antibody (Affinity BioReagents, Golden, CO), rabbit polyclonal anti-PSA antibody (Dako, Carpinteria, CA), rabbit monoclonal anti-PTEN antibody (Cell Signaling Technologies, Beverly, MA) and rabbit monoclonal anti-ERG antibody (Epitomics, Burlingame, CA) were used for immunohistochemistry. Biotinylated anti-rabbit IgGs and peroxidase-linked avidin/biotin complex reagents were obtained from Vector Laboratories.
Control sections were processed in parallel with rabbit nonimmune IgG (Dako, Carpinteria, CA) used at the same concentrations as the primary antibodies.

**Copy number and gene expression analysis**

For DNA and RNA isolation, patient and xenograft tumor sections were processed as previously described (22). We performed genome copy number (CN) profiling using the Agilent SurePrint G3 Human CGH 4x180K and 8x60k Microarray platforms. 0.5 μg of genomic DNA was used for hybridization, according to the manufacturer standard protocols as previously described (7, 22). Limited sample availability of patient samples 972 and 1005 prevented aCGH analysis. Instead, from these 2 patients, we used DNA-Seq derived copy number profiles which were published previously (7). All CN profiles were visualized and analyzed using the Biodiscovery Nexus Copy Number software package v6.0. The hierarchical clustering used complete linkage and a Euclidean distance metric.

For gene expression, total RNA samples were prepared following Agilent’s One-Color Microarray-Based Gene Expression Analysis Low Input Quick Amp Labeling v6.0. An input of 100ng of total RNA was used to generate Cyanine-3 labeled cRNA. Samples were hybridized on Agilent SurePrint G3 Human GE 8x60K Microarray (Design ID 028004). Arrays were scanned with the Agilent DNA Microarray Scanner at a 3um scan resolution and data was processed with Agilent Feature Extraction 10.10. Processed signal was quantile normalized with Agilent GeneSpring 11.5.1. Hierarchical clustering of gene expression data was performed using distance metrics calculated from pairwise correlation coefficients. Comparisons between samples were carried out using fold change of expression. Gene Ontology term enrichment was performed
using DAVID Bioinformatics Resources v6.7 (23). aCGH copy number and microarray gene expression data is available at GEO accession number GSE41193.

**Sequence data analysis**

Matched whole-genome sequencing (DNA-seq) and transcriptome sequencing (RNA-seq) of LTL331 and LTL331R was performed at BCCA Michael Smith Genome Sciences Centre according to standard protocols. For analyses of RNA-seq data (including the NEPC clinical cohort (24)) reads were first mapped onto the HG19 genome and exon-exon junctions by splice-aware aligner Tophat, using the known gene model annotation from Ensembl release 62. Reads with an unmapped mate or multi-mapped location were filtered out using Bamtools and PCR or sequencing optical duplicates were marked and removed by Picard. Based on the alignment of RNA-seq reads, gene expression profiles for each sample were calculated based on the gene annotation (Ensembl release 62). Only reads which were unique to one gene and exactly corresponded to gene structure were assigned to the corresponding genes. Raw read counts were normalized by R package DESeq across all samples. Adenocarcinoma samples were compared to NEPC samples using fold change in gene expression. Fusion transcripts and associated genomic breakpoints in LTL331 and LTL331R (Supplementary Fig. S8) were identified from RNA-Seq and DNA-Seq using the nFuse algorithm (25). To validate fusion junctions, primers were designed that flanked the predicted fusion position, and PCR reactions were performed to amplify the fusion fragments from cDNA. All amplification products were sequenced with ABI PRISM 310 Genetic Analyzer using standard techniques to confirm identity.
RESULTS

Generation and maintenance of transplantable patient-derived tumor lines

Directly after surgery or biopsy, fresh primary or metastatic prostate cancer samples from 18 patients (collected February 2008 to May 2010) were transplanted into the subrenal capsule (SRC) of male NOD-SCID mice supplemented with testosterone. Tumors from 2/18 patients were terminated due to development of B-cell lymphoma (26), while 9/16 were viable but static for >2 years after grafting. However, tumors from 7/18 patients, including 5 needle biopsy samples from 1 patient, showed robust growth after an initial latency period (time from initial engraftment until tumor volume reaches 100 mm³) ranging from 3 to 37 months (median 22 months; Table 1). From these 7 patients we established and expanded 12 transplantable tumor lines for a minimum of five generations of serial passaging (Table 1; Fig. 1; Fig. 2; Supplementary Fig. S1; www.livingtumorlab.com). Nine transplantable tumor lines were developed from primary tumors (5 different patients). Furthermore, 7 of these lines were derived from needle biopsies (3 different patients), the first time needle biopsies have been captured in a patient-derived xenograft model, and a significant step forward, given the critical node prostatic biopsies occupy in clinical diagnostic decisions. Small pieces of xenograft tissue (1mm³) from all transplantable tumor lines were collected at early generations (e.g. <5 generations) and frozen with DMSO. These stocks are maintained in liquid nitrogen tanks as frozen seeds, and can be recovered in NOD-SCID mice (mean recover rate using SRC grafting was 95%).

The two transplantable tumor lines with the briefest latency before line establishment (3 and 6 months), and the fastest tumor volume doubling time (10-12 days), were derived from metastatic neuroendocrine prostate cancers (NEPC) (Table 1). This is consistent with the clinic,
where NEPC is an aggressive histopathological subtype of prostate cancer for which there is no effective therapy (27). The remaining 10/12 transplantable tumor lines represent adenocarcinoma, the dominant histopathological subtype in the clinic (95% of diagnoses). In adenocarcinoma lines tumor volume doubling time ranged from 10 to 23 days. Apart from the initial latency period after patient tumor engraftment, once lines were established there was no latency at each generation of serial transplantation.

**Preservation of donor prostate tumor histopathology**

All transplantable tumor lines retained the major histopathological characteristics of their matched patient tumor (Table 1; Fig. 2 and Supplementary Fig. S1). In at least three serial generations of each adenocarcinoma line we observed conservation of either the glandular structure or solid sheet, depending on the differentiation status of the original patient tumor. Furthermore, each line retained expression of markers of prostatic adenocarcinoma, e.g. androgen receptor (AR) and prostate specific antigen (PSA). The two NEPC xenografts exhibited solid sheets of round/oval tumor cells with minimal cytoplasm and frequent mitotic figures, consistent with clinical NEPC. The lines were negative for AR and PSA expression but positive for the NEPC markers chromogranin A (CHGA) and synaptophysin (SYP). Accordingly, PSA was undetectable in the serum of hosts bearing NEPC lines. In contrast, serum PSA in all adenocarcinoma line hosts broadly corresponded to tumor volume (Supplementary Fig. S2).
Conservation of patient tumor molecular characteristics and prostate cancer heterogeneity

Chromosomal aberration is a sentinel feature of many cancers, and the associated gene deregulation and genome instability is implicated in the development and progression of prostate cancer (5, 6, 28-30). Combined genome copy number analysis of each independent transplantable tumor line demonstrated that they recapitulate both the heterogeneity of prostate cancer and key chromosomal alterations frequently observed (Fig. 3A) (6, 31). For example, in agreement with published patient tumor cohorts, we observed frequent loss of 8p and key tumor suppressors such as TP53, NKX3-1, RB1; as well as gains of 8q and oncogenes such as ETV1, EZH2 and BRAF (Fig. 3A). 6/7 independent tumor lines (11/12 overall) showed homozygous or heterozygous loss of PTEN, which was consistent with PTEN protein expression (Table 1; Fig. 1; Supplementary Fig. S1).

Where comparisons between patient tumor and xenograft were possible (n=5), the chromosomal copy number profiles in the transplantable tumor lines closely resembled the original tissues (Fig. 3B; Supplementary Fig. S3 and S4). Unsupervised hierarchical clustering of copy number segmentation profiles confirmed that all patient and xenograft pairs cluster together, further suggesting conservation of gross genome structure (Fig. 3C). In a recent study, we demonstrated that one of these models (LTL352) retained not just the gross genome structure, but also the expression profile of the parent tumor (7). Consistent with this finding, the transplantable tumor lines with matched patient tumor gene expression demonstrated high conservation of gene expression levels (Fig. 3D; Supplementary Fig. S5).

Gene expression profiling further demonstrated the diversity and heterogeneity captured by the xenograft lines (Fig. 3E). Expression of TMPRSS2-ERG marks 20-50% of prostate cancer,
and is believed to be an early event in carcinogenesis (3, 32-34). Transplantable tumor lines LTL310, LTL331 and LTL313A-H were developed from TMPRSS2-ERG positive tumors and accordingly expressed TMPRSS2-ERG at the mRNA level (Fig. 3E) and high levels of ERG at the protein level (Table 1; Fig. 1; Supplementary Fig. S1). NEPC lines LTL352 and LTL370 lines exhibited an interstitial deletion between TMPRSS2 and ERG (Supplementary Fig. S3), but no ERG expression was detectable, presumably since the androgen responsive gene TMPRSS2 is no longer under transcriptional pressure. The LTL418 tumor line was TMPRSS2-ERG negative, but exhibited high expression of ETV1 (Fig. 3E), potentially indicating an ETV1 rearrangement. After ERG, ETV1 is the most common overexpressed ETS gene in prostate tumors. LTL412 and LTL311 were apparently ETS fusion negative. LTL412 was developed from a metastatic tumor, treated for 5 years with anti-androgen therapy, and exhibited clear signs of response to therapy, including expression of constitutive active forms of the AR (7).

Aware of the potential for transplantable tumor lines to evolve after serial passaging in mice and diverge from the original molecular characteristics, we compared copy number and gene expression profiles of late generations to those of early generations (Supplementary Fig. S4 and S5). After serial passaging, only minimal changes were observed in gross genome copy number. Nevertheless, the preservation of early generations as frozen stock means any divergence can be circumvented if necessary.

**Different biopsy foci recapitulate functional heterogeneity**

Five of the transplantable tumor lines (LTL313A-H) were derived from needle biopsy specimens from 5 different foci of a patient’s primary tumor (Fig. 4). The slow-to-develop nature of prostate cancer means that at diagnosis a prostate can frequently be colonized by multiple
subpopulations of cancer cells, each with potentially different aggressiveness. Understanding this heterogeneity molecularly is of fundamental importance, as critical diagnostic decisions and prognostic predictions are heavily influenced by biopsy. Interestingly, the LTL-313 tumor lines showed different metastatic ability and growth rates \textit{in vivo} (Fig. 4A and B). For example, mice harboring LTL313H reproducibly developed microscopic metastases in the lung (29/34 mice), while LTL313B exhibited very low metastatic potential (1/11 LTL313B mice developed metastases). Copy number profiling revealed that all five lines shared major chromosomal alterations, e.g. \textit{PTEN} deletion and \textit{TMPRS2-ERG} interstitial deletion, and exhibited a broadly similar pattern of aberration, suggesting all lines share a common ancestor (Fig. 4B and C; Table 1). However, several unique chromosomal alterations were only observed in particular tumor lines, including for example, deletion of BRCA2 and RB1 in LTL313H (Fig. 4C). Therefore, despite the likely mono-clonal origin of each biopsy foci, during the colonization of the prostate by the predominant clone, individual populations diverged, creating a series of functionally heterogeneous subpopulations, which are represented by LTL313A-H.

\textbf{Response to androgen deprivation is consistent with the clinic and leads to the development of castrate-resistant prostate cancer}

Since androgen deprivation can lead to CRPC in patients, we examined the response of tumor lines to host castration and Bicalutamide treatment (a front-line therapy in the clinic). Host castration resulted initially in a dramatic drop in tumor volume and PSA levels of all adenocarcinoma line hosts, while NEPC lines continued to grow in the absence of androgen (Supplementary Fig. S2A). Bicalutamide treatment also resulted in a drop of tumor volume in all adenocarcinoma lines tested; a clinically-relevant finding given almost all patients respond
initially to this therapy (Supplementary Fig. S2B; Supplementary Table S1). In LTL313B and LTL331 we observed reproducible castrate-resistant growth (LTL313BR and LTL331R) after several months post-castration (Fig. 5A-C; Supplementary Fig. S6). LTL313BR retained protein expression of AR and PSA, therefore representing the majority of clinical cases where CRPC remains dependent on AR signalling. However androgen deprivation can also lead to the development of NEPC: it is estimated that up to 100% of CRPC have a NEPC component (35).

Although histologically and molecularly LTL331 is a typical adenocarcinoma, LTL331R was entirely AR and PSA negative and uniformly expressed a range of neuroendocrine markers including SYP, CHGA, CHGB and CD56 (Fig. 3E; Fig. 5A; Supplementary Fig. S6). LTL331R retained its neuroendocrine phenotype and androgen-independent growth when regrafted into either intact, testosterone-supplemented or castrated hosts, which suggested a stable and irreversible transformation (Supplementary Fig. S6). We performed RNA and DNA sequencing of LTL331 and LTL331R. At the gene expression level LTL331R was highly similar to clinical NEPC tumours, with up-regulated genes including a broad spectrum of neuronal transcription factors, membrane ion channels, receptors and secreted peptides (Supplementary Fig. S7). Both LTL331 and LTL331R exhibited very similar copy number profiles (Fig. 5C), and all fusion genes expressed in LTL331 were also identified in LTL331R, with the exception of TMPRSS2-ERG (lost due to the absence of AR expression; Supplementary Fig. S8). This data, together with the absence of NEPC cells in LTL331 pre-castration (Supplementary Fig. S8), indicates an adaptive response of the major population of adenocarcinoma cells rather than clonal selection of existing NEPC cells. The transformation appears to represent neuroendocrine transdifferentiation, where NEPC evolves directly from adenocarcinoma cells (36, 37).
Hypothesizing that LTL331 may be ‘predisposed’ to transdifferentiate we identified 549 up-regulated and 362 down-regulated genes in our microarray data whose expression were altered in LTL331 relative to other adenocarcinoma xenografts and concomitantly altered in the same direction in the NEPC LTL331R (Fig. 5D; Supplementary Fig. S9). We compared this list of genes to those showing the same trend in an unique clinical cohort comparing 7 NEPC tumors to 30 adenocarcinoma tumors (24). There was high overlap between the gene lists emerging from xenograft comparisons and the clinical data, further highlighting the fidelity of our models, with 254 up- and 185 down-regulated genes shared (Fig. 5D; Supplementary Table S2). The up-regulated signature was highly enriched for genes involved in neuron differentiation (GO:0030182; Benjamini-Hochberg corrected p=4.4x10^{-5}), and included key regulatory genes such as MYT1, PROX1, DPYS5L, APLP1, CELSR3, WDR62, UHRF1 and MYBL2. Evaluation of these genes in another independent clinical cohort of 216 adenocarcinoma cases with significant follow-up (6), demonstrated that they show altered expression in <10% of cases and association with poor outcome, consistent with the low incidence and lethality of NEPC in the clinic (Supplementary Fig. S9). Importantly, this set of genes was not consistently co-expressed with known neuroendocrine markers, suggesting their differential expression may not originate from NEPC foci in adenocarcinoma tissue.

Xenografts are associated with clinical outcome and provide retrospective prognostic information

Despite successful establishment of 12 lines from 7 different patients, tumors from 9/16 of the original patients failed to exhibit significant growth after two and half years of serial passaging in mice. These ‘static’ xenografts still exhibited healthy and viable tissue (Fig. 5E),
suggesting tumor quiescence. To our knowledge, the survival of healthy human tissue in the absence of growth for this length of time is quite unprecedented and highlights the remarkable fidelity of the SRC grafting process. Interestingly, the failure or success of xenograft line development provided retrospective prognostic information (Supplementary Table S3). Firstly, only 2/9 of the patients whose grafted tumors remained static had a PSA recurrence, compared to all (7/7) whose tumors led to successful xenograft line development (p=0.0032, Fisher’s Exact Test). Secondly, the patients whose grafts developed into transplantable tumor lines demonstrated poorer overall survival compared to those whose grafts were static (p=0.0389, Logrank test; Fig. 5F). Finally, we also observed that within the LTL panel latency brevity before tumor line development was significantly correlated with time to PSA recurrence in the patient (r²=0.83; p=0.0044; Supplementary Fig. S2C).

**DISCUSSION**

We have established a bank of transplantable patient-derived prostate tumor xenograft models that, for the first time, capture the diverse heterogeneity of primary prostate cancer. Our work showed that (1) subrenal capsule grafting of intact prostate tumors yields a very high success rate of tumor line development; (2) it is possible to generate transplantable tumor lines from primary prostate tumors and even from needle biopsy specimens; (3) the lines retained salient features of the original patient tumors, including histopathology, clinical marker expression, chromosomal aberration, gene expression profiles and tumor aggressiveness; (4) the lines span major histopathological and molecular subtypes of prostate cancer, capturing the diverse heterogeneity observed in the clinic for the first time; (5) host castration elicited a varied response, including progression to AR-dependent CRPC and neuroendocrine transdifferentiation;
and (6) success of tumor line development provides potential prognostic information for disease recurrence.

Although we, and others, have previously established the advantage of SRC grafting over traditional subcutaneous sites (19), previous reports focussed on the first generation of grafts with relatively short observation time, e.g. 3 months (18, 38, 39). As such, transplantable tumor lines, akin to those presented here, were not developed. One of the major advantages of SRC grafting over traditional subcutaneous grafting is the high tumor take rate (94%) and success rate of transplantable tumor line development (44%); largely due to the vascularization of the kidney (40, 41). The abundant supply of nutrients, hormones, growth factors and oxygen to transplanted cells and tissues (before they become vascularized) at the SRC site is likely instrumental to the success of the engraftment, and the conservation of patient tumor properties (42-44). The only property which we did not observe in our models is the propensity of clinical prostate tumors to metastasize to the bone. This is probably due to the difference in bone marrow microenvironment between human and mouse (45, 46).

Intra-tumoral heterogeneity within clinical samples presents significant difficulties for researchers attempting to functionally dissect cancer biology. For example, it has been reported that lethal metastases can arise from one cancer cell precursor (47), but isolating the particular sub-population most likely to metastasize from within a mixed total population is fraught with challenges. Therefore, our development of multiple transplantable tumor lines (LTL313A-H) from same patient’s different primary tumor biopsies, provides a next-generation model of intra-tumoral heterogeneity. Conserved genomic aberrations suggest that these 5 lines were clonally related, but they exhibited varied metastatic potential, growth rates and response to castration (development of CRPC in LTL313BR). We anticipate that detailed molecular analyses of these
lines will allow an increased understanding of disease progression and the identification of biomarkers for metastasis. Limited successes are beginning to emerge, with the identification of differentially expressed miRNAs between the metastatic and non-metastatic lines, LTL313B and LTL313H (48).

Success or failure of tumor line development highlights the clinical-relevance of our model system. Patients whose grafted tumors developed into transplantable tumor lines had significantly worse clinical outcome than those patients whose grafts remained static. Therefore, the ability of a grafted tumor to grow and thrive within the host appears to be linked to its aggressiveness in the patient, as opposed to experimental variability (a similar observation has been noted in breast cancer xenograft models (49)). Murine stromal infiltration was observed in both the static grafts and the transplantable tumor lines, consistent with previous studies (49, 50) and suggesting that the quiescent state is independent of mouse stroma. It is likely that the static tumors reflect the common clinical scenario where a proportion of patients have slow growing cancer which can be managed through active surveillance. Interestingly we also observed that latency (the time from initial engraftment to tumor line development) was significantly correlated with matched patients’ time to PSA recurrence, providing retrospective prognostic information. All our adenocarcinoma lines respond to androgen-withdrawal and Bicalutamide treatment, consistent with the clinic where almost all patients initially respond to androgen-withdrawal therapy. A large fraction of patients eventually fail androgen-ablation therapies and relapse with CRPC: a scenario also observed in our models, where two tumor lines relapsed as CRPC, several months post-castration.

Since CRPC is responsible for the majority of patient deaths, the development of CRPC directly from two hormone naïve patient-tissue derived lines will be useful for understanding and
combatting therapy resistance. Furthermore, the complete transformation of adenocarcinoma in LTL331 to uniform NEPC observed in the CRPC LTL331R, (in contrast to previously reported xenografts derived directly from clinical NEPC samples (14, 51)) represents the first time neuroendocrine transdifferentiation has been captured in a pre-clinical model, and provides strong evidence for epithelial plasticity. Although current therapeutic development focuses on AR-dependent CRPC, there are no targeted treatments for NEPC, and it is hypothesized that the emergence of more potent androgen deprivation therapies (e.g. Enzalutamide (52) and Abiraterone (53)) will increase the incidence of treatment-induced NEPC. Therefore, our unique model of neuroendocrine transdifferentiation provides a valuable tool for studying mechanisms of NEPC development and developing novel therapeutic avenues. Indeed, the power and fidelity of this model was demonstrated by a gene expression comparison leveraging clinical cohorts: generating a set of genes potentially involved with neuroendocrine transdifferentiation. Continued refinement of the emergent gene set using higher resolution technologies is undoubtedly necessary, but the potential for their development as novel molecular markers to aid risk stratification and predict therapy response is clear.

First or early generation xenografts which closely mimic a patient’s cancer, are especially suitable for ‘personalized oncology’, where the most effective and least toxic chemotherapeutic regimen is chosen for a patient (16, 54, 55). Early generation SRC grafts feature most, if not all, of the molecular heterogeneity and histological complexity that exist in a patient's original cancer. Importantly, all transplantable tumor lines are preserved as frozen stocks at early generations ensuring that cellular characteristics and composition are maintained, and allowing reproducible and reliable results. The ability to successfully develop transplantable tumor lines from patient tumor needle biopsy specimens (LTL310, 311, 313A-H) is highly clinically
relevant. In prostate cancer, biopsies are typically obtained at diagnosis, and with 98% of patients surviving >10 years after diagnosis, the time-frame for personalized oncology based on an understanding of an individual’s biopsies is clearly realistic. Needle biopsy specimens are more practical to obtain than prostatectomy samples, and since they are taken prior to prostatectomy, their analyses buys time to develop appropriate therapeutic strategies if necessary. Furthermore, since we demonstrated that grafted tumor growth was correlated with poor clinical outcome, they may help distinguish aggressive from indolent disease.

Beyond personalized oncology, we anticipate that our transplantable tumor lines will provide models for pre-clinical drug evaluation. The potential for this is evidenced by two recent studies which used LTL352 in combination with advanced genomic and transcriptomic profiling to identify and test new drug targets (24, 56). Moreover, translational research using LTL313 led to discovery of an anti-AR small molecule (57) and a drug candidate, OMN54, which has advanced to a Phase I clinical trial (ClinicalTrials.gov Identifier: NCT01555242). In recognition that the SRC grafting method is technically more demanding than the widely-used subcutaneous method, our models are publically available to the research community (http://www.livingtumorlab.com).

Furthermore, several of the LTL models (e.g. LTL331R and LTL352), once established, can be grafted subcutaneously either from fresh tissue or frozen seeds. Therefore, we anticipate that our panel of xenograft models, covering a number of molecular subtypes, will deliver clinically-relevant model systems for the development of novel therapeutic approaches to prostate cancer.
REFERENCES


### TABLE 1: Histopathological and molecular characteristics of LTL xenograft models and corresponding original tumors.

<table>
<thead>
<tr>
<th>Tumor line ID</th>
<th>Source</th>
<th>Diagnosis</th>
<th>AR</th>
<th>PSA</th>
<th>SYP</th>
<th>Latency† (months)</th>
<th>Doubling time†† (days)</th>
<th>Androgen sensitivity</th>
<th>Metastasis</th>
<th>AR</th>
<th>PSA</th>
<th>SYP</th>
<th>SPINK1</th>
<th>ERG</th>
<th>TMPRSS2-ERG</th>
<th>PTEN gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTL310</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>37</td>
<td>ND</td>
<td>No</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>ND</td>
<td>-</td>
</tr>
<tr>
<td>LTL311</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>14</td>
<td>10</td>
<td>Yes</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LTL331</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>17</td>
<td>9</td>
<td>Yes</td>
<td>tNEPC*</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>LTL412</td>
<td>L.N. metastasis</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>8</td>
<td>16-19</td>
<td>No</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
</tr>
<tr>
<td>LTL418</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>8</td>
<td>17-19</td>
<td>No</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+/+</td>
<td>-</td>
</tr>
<tr>
<td>LTL313A</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>22</td>
<td>10-14</td>
<td>Yes</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
<tr>
<td>LTL313B</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>22</td>
<td>11-20</td>
<td>No</td>
<td>Partial*</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
<tr>
<td>LTL313C</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>22</td>
<td>23</td>
<td>Yes</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
<tr>
<td>LTL313D</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>22</td>
<td>11-15</td>
<td>Yes</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
<tr>
<td>LTL313H</td>
<td>Primary PCa</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>13</td>
<td>11-13</td>
<td>Yes</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
<tr>
<td>LTL352</td>
<td>Urethral metastasis</td>
<td>NEPC</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>3</td>
<td>11</td>
<td>Yes</td>
<td>No</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+/+</td>
<td>+/-</td>
</tr>
<tr>
<td>LTL370</td>
<td>Penile metastasis</td>
<td>NEPC</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>6</td>
<td>13</td>
<td>Yes</td>
<td>No</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+/+</td>
<td>+/-</td>
</tr>
<tr>
<td>LTL313BR</td>
<td>LTL313B</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>N/A</td>
<td>17-18</td>
<td>ND</td>
<td>No</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
<tr>
<td>LTL331R</td>
<td>LTL331</td>
<td>AC</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>N/A</td>
<td>6-8</td>
<td>Yes</td>
<td>No</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-/-</td>
<td>-</td>
</tr>
</tbody>
</table>
LEGENDS FOR ALL TABLES AND FIGURES

Table 1: Histopathological and molecular characteristics of LTL xenograft models and corresponding original tumors. All expression status refers to protein expression unless otherwise stated. PCa = prostate cancer; AC = adenocarcinoma; NEPC = neuroendocrine prostate cancer; tNEPC = treatment-induced transdifferentiation into NEPC; † Latency refers to the time taken from initial engraftment until establishment of a transplantable tumor line; †† Doubling time refers to the tumor volume doubling time of each transplantable tumor line once established; * indicates a relapse after an initial response to castration.

Fig. 1: Schematic summary of the transplantable tumor line xenograft models.

Fig. 2: Transplantable tumor lines retain the histopathological characteristics of their original patient tumor. Transplantable tumor lines LTL331 and LTL352 show similar tissue structure to the patient tumor from which they were originally derived (H&E stain). Immunohistochemical stains show that the protein expression of key markers (AR, PSA, PTEN, ERG, SYP) is also conserved. Note that LTL331 represents adenocarcinoma, while LTL352 is a neuroendocrine prostate tumor. Scale bars are 100µm.

Fig. 3: Copy number and gene expression analysis of the xenograft models. A) Genome copy number analysis of each independent transplantable tumor line. Each tumor line is represented by an aCGH-derived heatmap (blue indicates a genomic gain and red indicates a loss). The frequency plots above and below the heatmaps demonstrate aberrations which are shared between multiple lines. Significant cancer genes are annotated. B) Example comparison between matched Patient 1015 and LTL418 demonstrating the conservation of chromosomal copy number status. C) Unsupervised hierarchical clustering of copy number profiles demonstrating
that each transplantable tumor line is most similar to its original patient tumor. D) Hexbin plots illustrating the high correlation of gene expression between xenografts and matched original patient tumors (see also Supplementary Fig. S5). E) Heatmap of selected gene expression levels across the transplantable tumor line cohort.

**Fig. 4:** LTL313 xenografts derived from multiple needle biopsies recapitulate functional heterogeneity of primary prostate cancer. A) Histopathology of each line demonstrating similar primary tissue structure (first panel), but different metastatic ability in the host (second panel) as evidenced by representative sections of host lung demonstrating presence or absence of microscopic metastases. Scale bars are 100µm. B) Graph illustrating the different growth rates of the LTL313 lines. C) Chromosomal copy number status in each line showing the similar patterns of aberration, highly suggestive of shared ancestry. Important prostate cancer genes affected by copy number gain or loss are annotated by arrowheads. Several examples of differences between lines are annotated, including focal variations on chromosomes 1 and 13.

**Fig. 5:** Emergence of castrate-resistant prostate cancer and clinical association of xenografts. A) Histopathological characteristics of castrate-resistant tumors LTL313BR and LTL331R, showing typical markers of AR-driven adenocarcinoma in LTL313BR but uniform expression of NEPC markers in LTL331R. B) Tumor volume and host plasma PSA levels in response to castration. C) Copy number profiles of LTL331 (before castration) and LTL331R (after relapse) demonstrating the high similarity, consistent with neuroendocrine transdifferentiation from adenocarcinoma cells. D) Venn diagram illustrating the intersection between genes up- or down-regulated in 3 different comparisons: LTL331 vs LTL331R, LTL331 vs all other adenocarcinoma xenografts (AD_LTL), and NEPC vs adenocarcinoma (AD) patient tumors. E) Histopathology of ‘static’ patient-derived xenografts illustrating that the tissue retains original
patient tumor histopathological characteristics after >2 years. F) Kaplan Meier plot demonstrating a significant difference in overall patient survival between patients whose tumors led to transplantable tumor lines and those whose grafts remained static.
Figure 4
Figure 5
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development

Dong Lin, Alexander W Wyatt, Hui Xue, et al.

Cancer Res  Published OnlineFirst December 19, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-2921-T

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2013/12/19/0008-5472.CAN-13-2921-T.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.